CN105025903B - 多汗症的治疗 - Google Patents

多汗症的治疗 Download PDF

Info

Publication number
CN105025903B
CN105025903B CN201380069414.3A CN201380069414A CN105025903B CN 105025903 B CN105025903 B CN 105025903B CN 201380069414 A CN201380069414 A CN 201380069414A CN 105025903 B CN105025903 B CN 105025903B
Authority
CN
China
Prior art keywords
use according
itpr2
rna molecule
medicament
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380069414.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105025903A (zh
Inventor
尼克拉斯·达赫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105025903A publication Critical patent/CN105025903A/zh
Application granted granted Critical
Publication of CN105025903B publication Critical patent/CN105025903B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201380069414.3A 2013-01-03 2013-12-13 多汗症的治疗 Active CN105025903B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361748592P 2013-01-03 2013-01-03
US61/748,592 2013-01-03
PCT/SE2013/051508 WO2014107124A1 (en) 2013-01-03 2013-12-13 Treatment of hyperhidrosis

Publications (2)

Publication Number Publication Date
CN105025903A CN105025903A (zh) 2015-11-04
CN105025903B true CN105025903B (zh) 2018-04-13

Family

ID=51062371

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380069414.3A Active CN105025903B (zh) 2013-01-03 2013-12-13 多汗症的治疗

Country Status (6)

Country Link
US (2) US9809820B2 (https=)
EP (1) EP2958572B1 (https=)
JP (1) JP6242402B2 (https=)
CN (1) CN105025903B (https=)
CA (1) CA2896939C (https=)
WO (1) WO2014107124A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809820B2 (en) * 2013-01-03 2017-11-07 Hidros Therapeutics International Ab Treatment of hyperhidrosis
WO2016150723A1 (en) 2015-03-20 2016-09-29 Unilever Plc Antiperspirant composition
CN110643598A (zh) * 2018-06-26 2020-01-03 煌鼎科技有限公司 促进皮肤凹疤愈合及毛孔收缩的酵母dna原料制法
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011690A1 (en) * 2000-08-03 2002-02-14 Unilever Plc Antiperspirant and deodorant products and methods for their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
ATE443765T1 (de) * 2003-03-21 2009-10-15 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
WO2005116204A1 (ja) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
ES2671874T3 (es) * 2007-10-18 2018-06-11 Rose U, Llc Formulaciones tópicas de glicopirrolato
CN102300578A (zh) 2008-12-01 2011-12-28 延寿有限责任公司 用于改变健康、安康和寿命的方法和组合物
WO2011020114A2 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
WO2012112422A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
US9809820B2 (en) * 2013-01-03 2017-11-07 Hidros Therapeutics International Ab Treatment of hyperhidrosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011690A1 (en) * 2000-08-03 2002-02-14 Unilever Plc Antiperspirant and deodorant products and methods for their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Abolished InsP3R2 function inhibits sweat secretion in both humans and mice;Joakim Klar, et al.;《The Journal of Clinical Investigation》;20141130;第124卷(第11期);4773–4780 *
An antidepressant behaviour in mice carrying a gene-specific InsP3R1, InsP3R2 and InsP3R3 protein knockdown;N. Galeotti, et al.;《Neuropharmacology》;20081231;第55卷;1156–1164 *
IP3 Receptor Types 2 and 3 Mediate Exocrine Secretion Underlying Energy Metabolism;Akira Futatsugi, et al.;《SCIENCE》;20050930;第309卷(第5744期);2232-2234 *

Also Published As

Publication number Publication date
US20160122770A1 (en) 2016-05-05
CA2896939C (en) 2022-07-12
JP6242402B2 (ja) 2017-12-06
WO2014107124A1 (en) 2014-07-10
US9809820B2 (en) 2017-11-07
EP2958572B1 (en) 2019-10-23
US10633661B2 (en) 2020-04-28
EP2958572A4 (en) 2016-12-14
CN105025903A (zh) 2015-11-04
CA2896939A1 (en) 2014-07-10
US20180044682A1 (en) 2018-02-15
JP2016505617A (ja) 2016-02-25
EP2958572A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
Vinaik et al. NLRP3 inflammasome activity is required for wound healing after burns
Yu et al. Adipose-derived exosomes protect the pulmonary endothelial barrier in ventilator-induced lung injury by inhibiting the TRPV4/Ca2+ signaling pathway
Duan et al. MicroRNA‐214 is upregulated in heart failure patients and suppresses XBP1‐mediated endothelial cells angiogenesis
US9994847B2 (en) miR-29 mimics and uses thereof
JP6140120B2 (ja) 挫瘡およびその他の状態を治療するためのビスファチン治療薬
WO2017143014A1 (en) Jak inhibitors and uses thereof
Ding et al. Simvastatin alleviated diabetes mellitus‐induced erectile dysfunction in rats by enhancing AMPK pathway‐induced autophagy
CN105025903B (zh) 多汗症的治疗
Song et al. Targeting a key pro-fibrotic factor S100A4 in cartilage to alleviate osteoarthritis progression and pain
US9234200B2 (en) Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector
JP2012502007A (ja) 強皮症の治療
US20220249511A1 (en) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
Morena et al. Promoting mitochondrial fusion is protective against cancer-induced muscle detriments in males and females
US12582649B2 (en) Compositions and methods for hair follicle regeneration
WO2022217035A1 (en) Activators of integrated stress response pathway for protection against ferroptosis
KR102740446B1 (ko) Linc00518 억제를 통한 베무라페닙 내성 흑색종 예방 또는 치료제, 및 그 스크리닝 방법
US20220313723A1 (en) Extracellular vesicles containing mir-142-3p to treat fibrosing diseases
WO2021147740A1 (zh) Mapk/erk通路抑制剂在拮抗皮肤老化与辐射性皮肤早衰中的应用
Matos et al. Combination therapy in Phe508del CFTR: how many will be enough?
US20260103712A1 (en) Anti-fibrotic microrna composition
CN121622722A (zh) miR-24及其类似物在防治皮肤炎症疾病中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant